ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TF Antibody-drug Conjugate MRG004A

Also written as “MRG004A” and “MRG004A plus best supportive care”.

Its studies are mostly in Pancreatic Neoplasms, led by Lepu Biopharma.

Furthest: phase 3, since Aug 17, 20252 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lepu Biopharma21 open or runningphase 3since Aug 17, 2025Apr 8, 2021Jun 2027phase 3 · NCT07138846

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2021First study: phase 2 study in Advanced or Metastatic Solid TumorsFirst studyNCT04843709 · 39 enrolled · United States, China
  2. Aug 17, 2025Phase 3 study in Pancreatic NeoplasmsNCT07138846 · 231 planned · China

Ahead

  1. Jun 2027Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07138846

TargetBeta

F3 →read by rule
“An antibody-drug conjugate (ADC) comprised of a monoclonal antibody against human tissue factor (TF) ”NCIt, by rule

Other programs on F3

ProgramCompanyFurthest phaseStudies
tisotumab vedotinrulePfizerphase 411
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012ruleEvopoint Biosciencesphase 33
SHR-4375Jiangsu HengRui Medicinephase 22
Anti-TF/TOP1i Antibody-drug Conjugate XB371ruleExelixisphase 11
Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rulesutro-biopharma-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07138846Pancreatic Neoplasms · China3Not yet recruitingJun 2027231
NCT04843709Advanced or Metastatic Solid Tumors · United States, China2CompletedMar 20, 202439

How it is read

Names in the registry

  • “MRG004A”, 1 entry
  • “MRG004A plus best supportive care”, 1 entry

Codes read as this program: MRG004A.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.